TarMart Solution Ecosystem & Related Targets
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ATN1 Wild-Type / Mutant (PolyQ Expanded) Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW. | View ATN1 Products |
| Gene Delivery | ATN1 Promise-ORF / Lentivirus. Full-length ORF (WT and Mutant) for stable cell lines. | View ATN1 Products |
| Benchmark Ab | Anti-ATN1 Control Antibody. Recombinant positive control for biomarker and expression detection. | View ATN1 Products |
| Validator | ATN1 siRNA Set. For knockdown verification and allele‑specific silencing. | View ATN1 Products |
| Related Target: HTT | Huntingtin. Paralogous polyQ neurodegeneration target for cross‑screening. | View HTT Products |
| Related Target: ATXN1 | Ataxin‑1. Shared polyQ expansion pathology mechanism. | View ATXN1 Products |
| Related Target: RERE | RERE (Atrophin‑2). Functional paralog and transcriptional interactor. | View RERE Products |
| Related Target: HDAC1 | Histone Deacetylase 1. Primary binding partner in ATN1 repression complex. | View HDAC1 Products |
| Related Target: REST | RE1‑Silencing Transcription Factor (NRSF). Scaffolding component of ATN1/HDAC repressor. | View REST Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| PolyQ Aggregation Modeling | Mutant recombinant proteins with defined CAG repeat lengths (Q17‑Q79), >95% purity, monomer‑enriched. |
| Allele‑Specific Silencing | Full‑length WT/Mutant ORF lentivirus for isogenic cell models; validated siRNA set. |
| WD40 Domain Integrity (PPI assays) | Full‑length proteins preserving C‑terminal WD40 repeats; mass spec verified. |
| Neuronal Cell Model Generation | Lentivirus titer >1E8 TU/mL for stable transduction of SH‑SY5Y/PC12 lines. |
| Aggregation Inhibition Screening | High‑purity substrates with controlled polyQ length for ThT and sedimentation assays. |
| False Positives in Knockdown | Validated siRNA included for strict specificity and viability checks. |
Global Clinical Landscape & Future Outlook
The therapeutic landscape for ATN1 is centered on Dentatorubral‑pallidoluysian atrophy (DRPLA), a rare neurodegenerative polyglutamine disorder. Current R&D is shifting from symptomatic management to disease‑modifying strategies targeting the toxic gain‑of‑function in expanded polyQ tracts. While no ATN1‑targeted therapy has reached Phase III, antisense oligonucleotide (ASO) strategies and small‑molecule aggregation inhibitors are advancing through preclinical and early clinical stages. Key players include Ionis Pharmaceuticals, Biogen, and academic consortia. Emerging research also explores ATN1's role in epigenetic dysregulation in oncology, positioning it as a potential synthetic lethal target. The next wave of R&D is targeting allele‑specific knockdown, targeted protein degradation (PROTACs), and CRISPR‑based gene editing to eliminate toxic ATN1 aggregates.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ASO / Gene Silencing | Ionis Pharmaceuticals, Biogen, Academic Consortia | DRPLA, PolyQ Disorders | Nuclear uptake & Allele‑selective knockdown (need lentivirus for stable neuronal lines). |
| Small Molecule Aggregase Inhibitors | Expansion Therapeutics, Academic Labs | PolyQ Diseases (DRPLA, HD) | Aggregation Kinetics Assay (need high‑purity mutant vs WT proteins). |
| PROTAC / Degraders | Preclinical (Undisclosed Biotech) | Proteinopathies | Binary/Ternary Complex Formation (need full‑length soluble antigen with intact WD40 domain). |
| Gene Therapy (AAV) | Neurodegeneration Gene Therapy Biotech | Rare Monogenic Diseases | Titer & Expression Validation (need ORF lentivirus controls). |
| Epigenetic Modulators | Oncology Biotechs | Transcriptional Cancers | HDAC1 Complex Disruption Assay (need ATN1‑HDAC1 PPI reagents). |
Live ATN1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: